

II

GROWTH

2

Molecular Mutations in the Human Growth Hormone Axis

Zvi Laron, MD

CONTENTS

INTRODUCTION
GROWTH HORMONE RELEASING HORMONE (GHRH)
THE GHRH-RECEPTOR (GHRH-R)
CONCLUSIONS
HUMAN PITUITARY GROWTH HORMONE (hGH)
MOLECULAR DEFECTS IN THE HUMAN GH GENE AND HORMONE
CONCLUSION
THE GROWTH HORMONE RECEPTOR
GROWTH HORMONE BINDING PROTEIN (GHBP)
MOLECULAR DEFECTS OF THE HUMAN GH RECEPTOR (LARON SYNDROME)
DEFECTS OF THE GH-RECEPTOR (GH-R)
PARTIAL GROWTH HORMONE INSENSITIVITY (GHI)
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1)
INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS (IGFBPs)
DEFECTS OF THE IGF-1 GENE AND RECEPTOR
GENOTYPE-PHENOTYPE RELATIONSHIP
ACKNOWLEDGMENT
REFERENCES

INTRODUCTION

Human growth hormone (hGH) is secreted from somatomammotrophic cells in the anterior pituitary in a pulsatile pattern that results from a diurnal rhythmically changing disequilibrium between two hypothalamic hormones: GHRH (GH-releasing hormone) and SMS (somatostatin = GH secretion inhibiting hormone) (1). GHRH induces hGH synthesis and secretion whenever the somatostatinergic tone is low (2). It is thus evident that SMS plays a central role in the regulation of GH secretion. The actions of SMS are not restricted to GH alone, but also affect other hormones, as seen in Fig. 1, which illustrates the GH cascade. Not illustrated is the inhibitory effect of somatostatin on TSH,

From: *Contemporary Endocrinology: Developmental Endocrinology: From Research to Clinical Practice*
Edited by: E. A. Eugster and O. H. Pescovitz © Humana Press Inc., Totowa, NJ




Fig. 1. The growth hormone axis. GH, growth hormone; GH-S, GH secretagog; GHRH, GH-releasing hormone; IGF-1, insulin-like growth factor-1; GHBP, GH binding protein; IGFBP, insulin-like growth factor; binding proteins; +, stimulates; -, inhibits.

and glucagon secretion (3). The regulation of somatostatin secretion is not yet completely elucidated, but there is evidence that insulin-like growth factor-1 (IGF-1) stimulates SMS (4), and that GH-S (GH secretagog) inhibit SMS secretion (5). Growth hormone secretagoges are small peptides, or nonpeptide substances synthesized in recent years, that act in synergism with GHRH to stimulate GH secretion (6). Several analogs of these substances have been found active in vitro and in vivo; however, whether they are natural products or man-invented pharmacological substances related to natural products remains to be elucidated. The finding of a GH-S receptor (7) indicated that such a hormone exists in reality.

Indeed recently Kojima et al. (8) described a 28 amino acid peptide extracted from the stomach that specifically binds to this receptor. It is called **GHRELIN** and releases GH both in vitro and in vivo. Its human gene has been encoded (8) and is located on chromosome 3p26-25 (9). It has 4 exons spanning 4.1 Kb of genomic DNA. The 117 amino acids have a 82% homology with the rat gene. It is also expressed in the arcuate nucleus of the hypothalamus (8).

Recent studies have shown a close relationship between Ghrelin and Motilin, another hormone synthesized in the stomach (10). Thus, the amino acid sequence of human prepro-motilin-related peptide (Prepro-MTLRP) is identical with human prepro-ghrelin, except Serine 26, which is not octanoylated in Prepro-MTLRP (11). Also the gastrointestinal motilin receptor (MTL-R) and the GHS-R are both G-protein-coupled receptors that show a high degree of homology (12). Motilin has also been found in the central nervous system (CNS) (13). Interactivity between these two hormones is not yet clear, but Ghrelin in addition to stimulating GH release in humans (14) releases appetite-stimulatory signals from the stomach (15), and induces adiposity in rodents (16). The orexigenic effect of Ghrelin does not seem to be GH-dependent, but acts by increasing hypothalamic neuropeptide y (NPY) (17). Standard meal intake after an overnight fast in 10 healthy young adults resulted in a significant decrease in plasma Ghrelin (120 min after the meal) correlating with the gastric emptying time (18). Thus Ghrelin seems to regulate between nutrient intake, gastric motility, and the CNS.




Fig. 2. Representation of chromosome 20 and location of the GHRH gene. Adapted with permission from ref. (26).

Ghrelin has also been identified in the placenta (19). Whether it plays a role in the secretion of placental lactogen remains to be established, as is the possibility that mutations in Ghrelin or its receptor may be involved in overeating and obesity.

The cloning of the genes of the hormones of the GH axis and their receptors in recent years and the advancement in molecular biology techniques have enabled the elucidation of the etiology of many conditions of abnormal growth. This chapter is a review of what is known at present on molecular defects in man related to the GHRH, GH, and IGF-1 molecules and their receptors, as well as a summary of the resulting clinical sequelae.

GROWTH HORMONE RELEASING HORMONE (GHRH)

Historical Perspective

In 1961, Reichlin demonstrated that lesions of the ventromedial nucleus of the rat hypothalamus resulted in cessation of growth as a result of GH deficiency (20). The isolation and characterization of human GHRH was made possible by the extraction of pancreatic tumors causing acromegaly (21,22).

The GHRH Gene

The GHRH gene is a member of a large family of hormones and factors, which includes glucagon, secretin, vasoactive intestinal polypeptide (VIP), and others (23,24). Humans have a single copy of the GHRH gene (25). It is localized on chromosome 20q12 and p11.23 (26) (Fig. 2) and has 5 exons spanning over 10 kilobase pairs (Fig. 3). GHRH is localized in the arcuate and ventromedial nuclei of the hypothalamus, but also in the




Fig. 3. Structure of the human GHRH cDNA and gene. GRF, GHRH. Adapted with permission from ref. (25).

gastrointestinal tract including pancreas (27), the testis and placenta (28), and other tissues as well as tumors (29,30).

Chemical Structure

GHRH is secreted in three molecular forms GHRH 1-44NH₂, GHRH 1-40-OH, and GHRH 1-37-OH (31). All three forms are biologically active, even a 1-29 fragment (32).

GHRH Gene Defects

Although isolated GH deficiency (IGHD) owing to complete or partial absence of GHRH has been diagnosed by indirect methods (33–35), no patients with a GHRH gene deletion or mutation in the GHRH gene have been described so far.

Clinical Aspects

The patients suspected or proved to have GHRH deficiency present the clinical and biochemical changes typical of IGHD (*see later*). The diagnosis is made by finding a GH response to GHRH and a negative one to insulin hypoglycemia and/or clonidine, or arginine.

THE GHRH-RECEPTOR (GHRH-R)

Historical Perspective

GHRH stimulates the transcription of the GH gene (36) and induces proliferation of the somatotroph cell (37) acting as a hypophyseotropic hormone. Successful cloning of the GHRH-R was achieved in 1992 by Mayo (38). This enabled a better insight into the mechanism of action of GHRH on the GH synthesis and secretion (39). The first abnormalities in the GHRH-R gene were detected in the little (lit) mouse (40), which paved the way to findings in man.

The Human GHRH Receptor Gene

The GHRH-R gene is located in the anterior hypophysis. GHRH stimulates adenylate cyclase resulting in increased cyclic adenosine monophosphate (cAMP) production indicating the intermediary action of a G-protein (41). The GHRH-R is homologous to a subfamily of G-protein-coupled receptors, which include VIP, GLP-1, secretin, glucagon, GIP, PACAP, calcitonin, PTH, and CRH (42). The human GHRH-R gene is located on chromosome 7p 13-p21 (43) (Fig. 4) and probably at p15 (44). It contains a frame of 1269




Fig. 4. Representation of chromosome 7 with location of the GHRH receptor gene. Adapted with permission from ref. (46).

bp coding for 432 amino-acids and 7 transmembrane-spanning helices (38) (Fig. 5). The mature GHRH-R is a 401 amino acid residue peptide with a large extracellular domain of 108 amino acids.

GHRH-Receptor Gene Mutations in Man

The finding of an inactivating mutation in the GHRH-R in the little (lit) mouse (40) suggested that similar defects may occur in man. So far four kindreds have been described, three originating from the Indian peninsula and one from Northeast Brazil (45–48). The first described patients by Wajnrajch et al. (45) are Indian Moslems and originate from Bombay. They belong to a very consanguineous kindred of which two cousins, a boy (age 16 yr) and a girl (3.5 yr) were investigated. Both were very short (–4.2 and –7.4 height SDS), and had frontal bossing and truncal obesity, the typical phenotype of severe isolated GH deficiency (IGHD) (49) or GH resistance (Laron syndrome; LS) (50). They had IGHD as demonstrated by no rise in serum GH upon oral clonidine, insulin hypoglycemia, and intravenous GHRH after sex-hormone priming. All other pituitary hormones were normal. DNA analysis revealed a nonsense mutation in the extracellular domain of the GHRH receptor, namely a G→T transversion at position 265 resulting in a Glu 72 stop (calculated with the signal protein). Treatment by hGH resulted in a growth spurt of 13 and 17 cm, respectively, in the first year of treatment.




Fig. 5. The GHRH receptor gene and the GHRH-R mutation in the Brazilian kindred (48). Adapted with permission from ref. (46).

The second consanguineous kindred originated in Sindh/Pakistan. Mahashwari et al. (46) examined 18 affected subjects, all very short (-7.2 to -8.3 height SDS), with a small head circumference (-4.3 SDS), possible facial hypoplasia, and some increase in adiposity. Puberty was delayed and the patients had high-pitched voices. Four patients had endocrine evaluations and no response of serum hGH was found to various stimuli, including GHRH. As expected, serum IGF-1 and IGFBP-3 were very low: 5.2 ± 2 ng/mL and 420 ± 130 ng/mL, respectively. Serum GHRH was found within the normal range and not elevated (46). DNA analysis revealed the same mutation as in the patients reported by Wajnrajch et al. (45).

Two additional brothers reported by Netchine et al. (47) were of Tamilian origin from Delf, an island between India and Srilanka. They were very short (-4 and -5 height SDS) and not responsive to GHRH stimulation. Despite having the same GHRH-R defect causing a truncated nonactive receptor as the patients previously reported, they had no frontal bossing, nor a small penis. MRI of the skull revealed a hypoplastic anterior pituitary. They too responded well to hGH therapy.

A fourth report coming from Itabaininha in Northeastern Brazil, a region with a population with a high degree of consanguinity, described 22 very short patients (-4.5 to -6 height SDS) belonging to a kindred of at least 105 affected families (48). Adult statures ranged from 105–135 cm; they were obese, had delayed puberty but normal




Fig. 6. The growth hormone and chorionic somatotropin gene cluster. Adapted with permission from ref. (84).

reproduction, and high-pitched voices. All 22 patients investigated had no response of hGH to stimuli including GHRH, and IGF-1 and IGFBP-3 were very low. DNA analysis revealed a novel mutation affecting the junction of exon 1 with intron 1 IVS1+1 G→A) (Fig. 5). Thirty of the affected subjects were homozygous for this mutation. The heterozygote subjects had a normal phenotype.

CONCLUSIONS

The patients with GHRH-R defects identified so far stem from inbred populations and all have been described to have various degrees of the typical phenotype of IGHD (49) or GH insensitivity (LS) (50). Of interest is the finding of a hypoplastic anterior pituitary in one report (47).

Diagnostic Hint

Patients with severe IGHD that show no rise of serum GH upon intravenous administration of GHRH should be screened for a defect in the GHRH-R.

HUMAN PITUITARY GROWTH HORMONE (hGH)

Historical Perspective

Human GH was isolated in 1956 (51) and its gene cloned in 1979 (52). The diagnosis of IGHD was made possible only after the introduction of specific radioimmunoassays (53) and immunocytochemistry (54).

The hGH Gene Family

Human GH consists of a cluster of five similar genes in the following order: 5 hGH-1, (or –N), CSHP (chorionic somatomammotropin pseudo gene, CSH-1 (chorionic somatomammotropin); hGH-2 (or V) or placental GH, which differs from the primary sequence of hGH-N by 13 amino acids (55) and replaces pituitary GH in the maternal circulation during the second half of pregnancy (Fig. 6). The hGH genes are located on a 78kb section of the long arm of chromosome 17q22-24 (56).

CSH-1 and CSH-2 encode chorionic somatomammotropin, and CSH-P gives rise to low levels of alternatively spliced mRNAs and does not encode a known hormone (57). Only hGH-1 has anabolic growth promoting actions. The genes for GH and chorionic somatomammotropins have 5 exons separated by 4 introns. The human CSH genes have no anabolic or growth activity (58).

hGH Chemical Structure

Human GH is produced as a single chain, 191 amino acid 22-Kd protein (59). It contains two disulfide bonds and shares homology with GH-2. Under normal conditions 75% of pituitary hGH is of the mature 22Kd form. Alternate splicing of the second codon resulting in deletion of amino acids 31–46 yields a 20 Kd form (about 5–10% of pituitary hGH) (60). A small amount of 17 Kd hGH is formed as well (61). The spectrum of biological activity of the 20 Kd hGH form is very similar to that of the 22 Kd hGH (62) although a lesser insulinotropic effect has been occasionally found.

The relationship between the integrity of the GH molecule and its biological activities has been a topic of great interest since the isolation of hGH. In contradistinction to ACTH and GHRH in which shortened molecules are fully active; with respect to hGH this seems to be true only for the 20 and 22 Kd variants. Nevertheless, it is of interest that hGH fragments 1-43 and 44-191 have been found to have potent *in vivo* effects on glucose homeostasis in rodents, and the 44-191 fragment has low-affinity binding to recombinant hGHBP (63).

MOLECULAR DEFECTS IN THE HUMAN GH GENE AND HORMONE

Abnormalities in the structure of the hGH molecule or GH gene deletion have been suspected to occur in humans for some time, but could not be proven until adequate laboratory methods were developed and the right patients found.

A seemingly innocuous defect is the omission of exon 3, which causes the production of 17 Kd hGH (64). hGH-N gene deletions are being diagnosed more and more frequently in patients with hereditary IGHD from consanguineous families. A classification attempt has been made (65) (Table 1). Three or possibly four forms of IGHD due to defects in the hGH-1 gene are now recognized. In some forms of familial IGHD the exact molecular defect has not yet been found.

IGHD Type IA

Type IA was first described by Illig et al. (66) in a Swiss inbred family. Phillips et al. (67) found that the etiology was the lack of the hGH-1 gene. There followed descriptions from other countries (68–81). The sizes of the deletions are heterogenous. DNA analysis revealed that most (70–80%) patients with IGHD Type I have a 6.7 kb deletion in the GH gene, the remainder (20–30%) have a 7.6 or 7.0 kb deletion (81).

The frequency of GH-1 deletions as a cause of IGHD varies among populations. Analyzing patients with severe IGHD (height SDS below 4) the prevalences cited by Mullis et al. (82) are 9.4% (Northern Europe), 13.6% (Mediterranean), 16.6% (Turkey), 38% (Oriental Jews), and 12% Chinese. Parks et al. (83) suggest that GH gene deletion is the most common cause of severe GHD among Oriental Jewish children. This seems to be true also for the Israeli Arab including Bedouin population (Laron, unpublished observation).

Table 1
Isolated Growth Hormone Deficiencies (IGHD)

Category	Inheritance	GH-RIA	Candidate Gene	Status
IGHD IA	Autosomal recessive	Absent	hGH-1	Deletions Mutations (signal peptide)
IGHD IB	Autosomal recessive	Absent/low	hGH-1 GHRH GHRH-receptor Trans-acting factors Cis-acting elements	Frameshifts Stop codon Splice site mutations Unlikely Mutations Mutations/deletions Mutations/deletions
IGHD II	Autosomal dominant	Low	hGH-1	Splice site mutations
IGHD III	X-linked	Low	Unknown	

Adapted with permission from ref. (65).

Dependent on the size of the deletion also the CSH cluster or hGH-2 genes can also be deleted (79), although the clinical implications of such deletions is unknown. Institution of hGH replacement therapy induces in most patients the formation of high titers of hGH antibodies leading to growth arrest (69). It is not yet understood why some patients do not develop antibodies (70,78). It seems that patients with a 7.6 kb gene deletion respond well to hGH treatment without antibody formation in contradistinction to patients with a 6.7 kb gene deletion. Gene deletion could result from incorrect alignment of chromosomes during meiosis.

Missense and nonsense mutations as well as small deletions of the GH-1 gene also cause familial IGHD (84). Thus a homozygous nonsense mutation in codon 20 of the signal peptide was reported in two patients of a Turkish family (85). Igarashi et al. (86) reported a Japanese compound heterozygote patient with a 6.7kb deletion and a 2bp deletion in exon 3 of the GH-1 gene, which produced a frameshift and generated a stop codon at amino acid residue 131 in exon 4. Nishi et al. (87) reported an affected child with a compound heterozygous deletion of 6.7 kb inherited from the mother and point mutations (at positions 123 and 250) inherited from the father. Phenotypically the patients are very short (> -4 SDS), with protruding forehead, acromicria, and obesity.

Treatment

The patients with hGH-1 gene deletions who do not develop antibodies against hGH or only low titers, can be treated by hGH (70,88). The patients who develop blocking antibodies to hGH need to be treated by IGF-1 (89).

Isolated GH Deficiency Type IB

IGHD Type IB is a not very clearly defined entity (65,90). It also has an autosomal recessive mode of inheritance and is characterized by low but detectable levels of serum hGH after stimulation (partial GHD). This is in contradistinction to Type IA IGHD where no circulating hGH is detectable. Cogan et al. (85) reported two patients from a Saudi Arabian family in which a first-base transition of the intron 4 (+1G→C) causes an activation of

a cryptic splice in exon 4, thereby deleting aminoacids 103 to 126 (in exon 4) and the frameshift in exon 5.

Recently, Abdul-Latif et al. (91) described several patients with IGHD belonging to a large consanguineous Bedouin kindred in Israel. They were short (height SDS between -3.6 to -5.2) and revealed no or very low-serum GH response to pharmacological stimuli. This family presented a novel mutation: a G→C transversion at the fifth base of intron 4, but it resulted in the same cryptic splice site as the patients from Saudi Arabia (85,90). The excess of patients with IGHD among Arab families may reflect the high incidence of consanguinity rather than spontaneous mutations (92).

Isolated GH Deficiency Type II

In contrast to IGHD Type I, IGHD Type II has an autosomal dominant mode of inheritance (65,84). The diagnostic criteria resemble IGHD Type IB. The patients are short but less than type IA and respond to hGH treatment. In a Turkish family a T→C transition of base 6 of the donor splice site of intron 3 caused the splicing out or skipping of exon 3 and the loss of amino acids 32–71 of the hGH molecule (81), so that the truncated molecule corresponds to the 17.5 Kd isoform of hGH. Saitoh et al. (93) reported a 1-yr-old Japanese boy and his father with IGHD. Both were found to have a G→C transition of the first base of the donor splice site of intron 3 of the hGH-1 gene.

Subsequently, a G→A transition at the first base of intron 3 has been identified in several families of different ethnic backgrounds (94–96). Recently Hayashi et al. (97) described a de novo mutation in a Japanese boy. He had a G→C transversion at the fifth nucleotide of intron 3, causing the skipping of exon 3.

Isolated GH Deficiency Type III

This type of IGHD has an X-linked recessive mode of inheritance. Some patients have hypo- or agammaglobulinemia (deficiency of IgG, IgA, IgM, and IgE) (98,99). As the hGH-1 gene is normal, this disease is considered to affect steps proximal to the hGH-1 gene (100) or a combination between X-linked agammaglobulinemia and hGH gene deletions (101). Some patients with IGHD have been found to have interstitial deletion at chromosome Xp22.3 (102) or duplication of Xq13.3-q21.2 (103). Recently four patients with 22q11.2 deletion, short stature and GH deficiency were reported (104). Two of them had a hypoplastic anterior pituitary gland and one of them also had an abnormal insertion of the infundibular stalk.

CONCLUSION

IGHD can be caused by various defects of the hGH-1 gene, from deletions to single mutations (105). Whereas IGHD Type IA and Type II seem clearly defined, the etiologies and definitions of Type IB and Type III remain to be improved.

Diagnostic Hint

Patients with severe IGHD, who show no rise of serum GH upon intravenous administration of GHRH should also be screened for a defect in the hGH-1 gene; patients with a family history of short stature and partial GHD on repeated tests, should also be investigated, as well as short children with immunoglobulin deficiencies.




Fig. 7. The localizations of the mutations of the hGH-1 gene leading to bio-inactive growth hormone. Adapted with permission from ref. (108).

Growth Hormone Deficiency Owing to Mutant Human Growth Hormone

Although the existence of short stature due to biologically inactive growth hormone had been postulated, the case was only proven recently. Takahashi et al. (106,107) reported the first documented patients. Both are products of nonrelated parents. The first patient (106) had a birth length of 39 cm and measured 81.7 cm at age 4.9 yr (−6.1 height SDS). He had a prominent forehead, serum hGH levels ranged from 7–14 µg/mL, and rose upon pharmacological stimulation to 35 µg/mL. Serum GHBP was low 70 pmol/L (normal: 107–337 pmol/L). Linear growth responded only temporarily to hGH. The molecular analysis of the hGH gene revealed a heterozygous missense mutation, which converted codon 77 in exon 4 from Arg→Cys (Fig. 7) (108). The second patient (107), a girl, was born with a normal length but slowed her growth so that at the age 3 she measured 79.4 cm (−3.6 height SDS). Her mother was also short (147 cm). She had a prominent forehead. Serum hGH rose from 11 to 26 µg/mL upon hypoglycemia stimulation and up to 51 µg/mL after intravenous GHRH. The low IGF-1 rose from 0.28 U/mL to 1.21 U/mL after 3 daily hGH injections and further after successful treatment (11cm/yr) of 1 yr hGH treatment. DNA analysis revealed a heterozygous missense mutation which converted codon 112 in exon 4 from Asp→Gly. The presence of mutant hGH was further confirmed in both patients by isoelectric focusing. In addition, the functional properties of the mutant hGHs were determined by the investigation. The 112 G mutant tended to form a 1:1 GH-GHBP complex instead of a 1:2 complex as produced by the wild-type hGH, a crucial step for GH signal transmission. Thus the mutant was less potent in the phosphorylation of JAK 2 and activation of STAT 5 in IM-9 cells (*see later*). In the case of the other patient, the affinity of the mutant hGH to GHBP was six times higher than the wild-type hGH, and acting as an antagonist failed to stimulate tyrosine phosphorylation and inhibited the activity of wild-type hGH upon simultaneous addition *in vitro*.

Diagnostic Hint

Whenever there is severe short stature (−3.5 height SDS or more) and the phenotype resembles IGHD, the serum hGH is measurable and responsive to stimuli, but serum IGF-1 is low and only partially responsive to exogenous hGH, the presence of a mutant, biologically inactive hGH molecule should be considered.




Fig. 8. The hGH receptor gene. Adapted with permission from ref. (111).

THE GROWTH HORMONE RECEPTOR

The growth hormone receptor (GH-R) belongs to the family of cytokine receptors which includes receptors for prolactin, erythropoietin, and interleukins (109). The human GH-R gene was cloned in 1987 by Leung et al. (110). It is a protein of 620 aminoacids and consists of 10 exons and spans 87 Kb (111). Exons 2 through 7 encode the extracellular domain (246 residues), exon 8 the single membrane-spanning domain (23 residues), and exons 9 and 10 the intracellular (cytoplasmatic) domain (351 residues) (Fig. 8) (111). The extracellular domain is identical in structure to the GH binding protein (GHBP) (110). The human GH-R gene is located on the short arm of chromosome 5p 13.1 (112).

GH-R form homodimers in the course of binding a single GH molecule (113,114). First the hGH molecule binds at binding site A and then at site B on the second receptor molecule. Sites A and B of binding on hGH are distinct but those on the GHBP overlap (115). The species specificity in the recognition of hGH by the human GH-R is claimed to reside in the interaction between an aspartic acid residue at position 171 of hGH with an arginine residue 43 of the GH-R (116). The binding sites of hGH to the GH-R are located in the cysteine-rich domain of the extracellular domain (115). Receptor occupancy leads to auto-phosphorylation of the Janus 2 (JAK 2) kinase (117) and subsequent phosphorylation of the receptor itself. The intracellular signalling cascade includes activation of mitogen-activated protein kinase (MAPK) and of transcription factors known as STATS (signal transducers and activation of transcription) (118).

GROWTH HORMONE BINDING PROTEIN (GHBP)

Herington et al. (119) and Baumann et al. (120) independently described a serum protein capable of binding GH with high affinity. This GH binding protein (GHBP) was shown to be identical in structure with the extracellular hormone-binding domain of the GH-R (110). Its quantitative measurements revealed that its serum concentrations change with age, being low in neonates and reaching maximal values in young adulthood (121). Whether GHBP can be synthesized de novo, in addition to being formed by the splicing of the extracellular domain of the GH-R (122) with which it shares structural identity (110) is not known. The presence of mutated GHBP in the circulation has not yet been described. Between 30–50% of the circulating GH is bound to this protein.

Determination of serum GHBP can be used as a simple quantitative estimation of the extracellular domain of the GH-R; its absence indicating a defect in this domain of the receptor and resulting in classical Laron syndrome (50,123,124). A low-serum GHBP concentration in relatives of patients with LS helps identify heterozygous carriers (125) of mutations in the extracellular domain of the receptor.




Fig. 9. Similarity between a boy with Laron syndrome (LS) and one with isolated GH deficiency (IGHD) due to GH-1 gene deletion.

Normal or elevated serum GHBP in typical LS patients denotes a defect in the trans-membrane, intracellular or downstream of the GH-R.

MOLECULAR DEFECTS OF THE HUMAN GH RECEPTOR (LARON SYNDROME)

Historical Perspective

The first description of patients with this syndrome was made by Laron et al. in 1966 (126) who reported 22 patients in 1968 (127). The patients resembled phenotypically those with IGHD (Fig. 9) but had excessively high circulating GH levels, and very low serum IGF-1 (sulfation factor) generation (128), which did not respond to administration of exogenous GH (129). The first assumption that the GH molecule is abnormal was excluded by findings between 1973 and 1985 that their high circulating hGH was normal both by immunologic (130,131) and radioreceptor testing (132,133). The proof that the GH resistance, the characteristic of these patients, is the result of a defect in the GH-R was provided by Eshet et al. in 1984 (134) by demonstrating that liver membranes of two patients prepared from open biopsies do not bind human GH. The cloning of the GH-receptor in 1986 (111) enabled the study of molecular defects.

Geographical Distribution

Following the early descriptions, patient reports from many continents followed, a majority originating from the Mediterranean, Mid-Eastern, or South Asian regions, known to have a high incidence of consanguineous marriages.

Today several hundreds of patients are known; the majority, though, are probably still undiagnosed. The largest cohorts known so far are in Ecuador: 79 patients (135), consisting of subjects originating in Spain, possibly of Jewish origin, and the Israeli cohort consisting of 51 Jews originating from Yemen, Iran, Afghanistan, Middle East, North Africa, and Israeli Arabs (136), with smaller cohorts in Turkey (137), Iran (138), India (123), and Bahamas (140). Patients in families or isolated patients have been reported from Italy, France, Spain, Denmark, Germany, Slovakia, Slovenia, Russia, Poland, North Africa, Japan, Vietnam, Cambodia, Mexico, and South and North America. They are listed in review papers (141–143). Recently an additional 14-yr-old girl of Slavic origin from Russia was reported (144).

Analysis of the Israeli cohort led to the conclusion that LS is caused by an autosomal fully penetrant recessive mechanism (145) with one exception of a father and two of his children in whom a dominant transmission is assumed (146).

DEFECTS OF THE GH-RECEPTOR (GH-R)

In 1989 Godowski et al. (111) characterized the genomic organization of the GH-R gene and reported two patients from the Israeli cohort who were homozygous for the deletion of exons 3, 5 and 6. In the same year Amselem et al. (147) using the newly developed polymerase chain reaction (PCR) methodology described several point mutations in patients with Laron syndrome. Since then a series of patients have been investigated and the findings are listed in Table 2 (148–163). As seen, the molecular defects range from deletions, nonsense-frameshift, splice to missense mutations. The majority of defects reported today are located in the extracellular domain of the human GH-R gene. In almost all instances the patients were found to be homozygous for the same mutant allele, as expected in recessive hereditary transmission. However, occasionally there were patients who were compound heterozygotes for mutations (160,161).

As the GHBP is identical in structure to the extracellular domain (110), mutations in this part of the receptor usually result in undetectable or very low serum GHBP. This measurement represents a simple and fast screening for the ascertainment of a molecular defect in the extracellular domain of the GH-R, and identification of heterozygotes for defects in this domain (125).

So far only two mutations in the transmembrane region (exon 8) (156,157) and three instances of mutations in the intracellular domain (exons 9 or 10) (159–161) have been reported. In all these patients the serum levels of GHBP are normal or high. The patients described by Ayling et al. (160) had a dominant transmitted single heterozygous mutation: from mother to daughter, a G→C transversion at 876-1 affecting the 3' splice receptor site preceding exon 9, causing the deletion. The patients of Iida et al. (161) also had a G→A transversion at 876, and also revealed a dominant negative transmission from mother to two children.

Post GH-R Defects

Until now only two reports on downstream defects in Laron syndrome have been described. Laron et al. (163) described three siblings of Palestinian Arab origin, with high serum hGH, normal GHBP, and a normal GH-R structure. Exogenous administration of hGH for 7 d did not raise the undetectable or very low-serum IGF-1, but caused a rise in serum IGFBP-3, indicating a functioning GH-R. The exact defect is under study. Freeth

et al. (164) described four girls with LS of two unrelated Asian families with normal GHBP in whom no mutations of the GH-R were detected. Further studies of the GH signaling pathway performed in skin fibroblasts of these patients (165) revealed that GH failed to activate the STAT pathway in fibroblasts of one family, being normal in the second family denoting different signalling defects in the two families.

Clinical Features

The clinical and biochemical characteristics of patients with primary IGF-1 deficiency (GH insensitivity = Laron syndrome) in childhood and adulthood are summarized in Table 3. Despite a wide spectrum of variability (141,143,146,166), the characteristic clinical features resemble IGHD (Fig. 9), i.e., severe growth failure (−4 to −10 height SDS), small cranium, underdevelopment of the facial bones resulting in protruding forehead (141), sparse hair (167), crowded and defective teeth (127), acromicria, and small genitalia and gonads (168). Most patients have a high-pitched voice (127,146). Body proportions show a high upper/lower ratio; skeletal maturation is markedly retarded (169), with osteopenia and osteoporosis developing in young adulthood (170). There is delayed motor development (50,127) and intellectual impairments of variable degrees (171). Puberty is delayed (172) but reproductive potential is preserved (50), the heterozygote children having a normal phenotype. Obesity is evident in young age and progresses markedly in adulthood (173), the patients also developing hyperlipidemia and insulin resistance despite a tendency for hypoglycemia (174). Final height ranges from 108–136 cm in females and 119–142 cm in males (50). Some of the patients with positive serum GHBP, i.e., those with a molecular defect in the transmembrane, intracellular, or postreceptor pathways, seem to be slightly less short (166,175). The few patients with a postreceptor defect seem to be less obese (163,164), possibly due to a preserved direct GH effect.

Nomenclature

The nomenclature used for this syndrome is confusing. A consensus nomenclature has been published, proposing that primary GH resistance or insensitivity (GHIS) be synonymous with Laron syndrome (LS), differentiating it from secondary GH resistance (176). Some authors use only GHIS, without differentiation; others use GH receptor deficiency (GHRD) (135,177).

Diagnostic Hint

The findings of abnormally high serum GH levels in patients with the clinical characteristics of IGHD should serve as an alert to the diagnosis of LS. The confirmation is low-serum IGF-1, which does not rise upon the daily administration of exogenous hGH for 4–7 d (129,146). Location of a defect in the extracellular domain of the GH-R is evidenced by a low or undetectable serum GHBP (119,120). The finding of a normal or high serum GHBP denotes a defect in the transmembrane or intracellular domain.

Treatment

The only possible therapy is administration of IGF-1, which has been practiced by us since 1988 (178) and subsequently by three other groups in the US, Ecuador, and Europe (179–181). IGF-1 stimulates linear growth (179–183), but is less efficient than hGH in the treatment of IGHD (184). IGF-1 treatment improves also biochemical abnormalities

Table 2
Growth Hormone Receptor Mutations Reported in Patients with Laron Syndrome^a

<i>Mutations</i>	<i>Molecular defect</i>	<i>Nucleotide change</i>	<i>Exon involved</i>	<i>Domain^b</i>	<i>GHBP^c</i>	<i>Authors</i>	<i>Reference</i>
Deletion	Exons 3-5-6		Exons 3-5-6	EC	—	Godowski et al. (1989)	(111)
Nonsense	C38X	C→A at 168	4	EC	—	Amselem et al. (1991)	(148)
	R43X	C→T at 181	4	EC	—	Amselem et al. (1991)	(148)
	Q65X	C→T at 197	4	EC	—	Sobrier et al. (1997)	(150)
	W80X	C→A at 293	5	EC	—	Sobrier et al. (1997)	(150)
	W157X	C→A at 525	6	EC	?	Sobrier et al. (1997)	(150)
	E183X	C→T at 601	6	EC	?	Berg et al. (1994)	(151)
	R217X	C→T at 703	7	EC	—	Amselem et al. (1993)	(152)
	Z224X	G→T at 724	7	EC	—	Kaji et al. (1997)	(242)
Frameshift	21delTT	delTT at 118	4	EC	—	Counts and Cutler (1995)	(153)
	36delC	delC at 162	4	EC	—	Sobrier et al. (1997)	(150)
	46delTT	delTTat192-193	4	EC	—	Berg et al. (1993)	(154)
	230delT	delT at 744	7	EC	—	Sobrier et al. (1997)	(150)
	230delAT	delATat 743-744	7	EC	—	Berg et al. (1993)	(154)
	309delC	delC at 981	10	IC	—	Kaji et al. (1997)	(242)
Splice	Intron 2	G→A at 70+1		EC	?	Sobrier et al. (1997)	(150)
	Intron 4	G→A at 266+1		EC	—	Amselem et al. (1993)	(152)
	Intron 5	G→A at 71+1		EC		Berg et al. (1993)	(154)
	Intron 5	G→C at 130-1		EC		Berg et al. (1994)	(151)
	Intron 6	G→T at 189-1		EC		Berg et al. (1993)	(154)
	Intron 5	G→C at 440-1		EC	—	Amselem et al. (1993)	(152)
	Intron 6	G→T at 619-1		EC	—	Berg et al. (1993)	(154)
	E180splice	A→G at 594	6	EC	+	Berg et al. (1992)	(155)
	Gly236GLY	C→T at 766		EC	—	Baumbach et al. (1997)	(140)
	G223G	C→T at 723	7	EC	—	Sobrier et al. (1997)	(150)
	Intron 7	G→C at 785-1	7/8	EC/TM	+++	Silbergeld et al. (1997)	(156)

	R274T	G→C at 874	8	TM	++	Woods et al. (1996)	(157)
	GHR(1-277) ^d	G→A at 876+1	9	TM/IC	++	Iida et al. (1998)	(161)
	GHR(1-277) ^e	G→C at 876-1	9	TM/IC	+	Ayling et al. (1997)	(160)
Missense	C38S	T→A at 166	4	EC	?	Sobrier et al. (1997)	(150)
	S40L	C→T at 173	4	EC	?	Sobrier et al. (1997)	(150)
	W50R	T→C at 202	4	EC	–	Sobrier et al. (1997)	(150)
	R71K	G→A at 266	4	EC	–	Amselem et al. (1993)	(152)
	F96S	T→C at 341	5	EC	–	Amselem et al. (1989)	(147)
	V125A	T→C at 428	5	EC	–	Amselem et al. (1993)	(152)
	P131Q	C→A at 446	6	EC	?	Walker et al. (1998)	(162)
	V144D	T→A at 485	6	EC	–	Amselem et al. (1993)	(152)
	D152H	G→C at 508	6	EC	+	Duquesnoy et al. (1994)	(158)
	R161C	C→T at 535	6	EC	–	Amselem et al. (1993)	(152)
	R211G	C→G at 685	7	EC	–	Amselem et al. (1993)	(152)
	C422F ^f	C→T at 1362	10	IC	–	Kou et al. (1993)	(159)
	P561T ^f	C→T at 1778	10	IC	–	Kou et al. (1993)	(159)

^aPrimary growth hormone insensitivity = resistance.

^bEC, extracellular; TM, transmembrane; IC, intracellular.

^c?, not available; +, detectable; ++, high levels; +++, very high levels.

^dat the +1 position of the 5'-donor splice site of intron 9.

^eat the 3'-splice acceptor site preceding exon 9.

^fThese two mutations were identified on the same GHR allele.

Table 3
Early and Late Consequences of Primary IGF-1 Deficiency^a

<i>Perinatal and during childhood</i>
Subnormal birth length (−10–30%)
Disproportional growth
Acromicria including facial bones
Defective and crowded teeth
Sparse hair growth
Small gonads and genitalia
Obesity
Retarded skeletal maturation
Retarded brain growth (head circumference)
Delayed motor development
Narrow larynx (high-pitched voice)
Delayed puberty
Hypoglycemia
High-serum GH
<i>Adulthood</i>
Very short stature (final height: 108–142 cm, i.e., −4 to −10 height SDS)
Marked progressive obesity
Osteoporosis
Muscle underdevelopment and weakness
Cardiomicria
Varying intellectual deficits (from retardation to normal)
Hyperinsulinemia
Hypercholesterolemia
Glucose intolerance and diabetes

^aGH insensitivity = Laron Syndrome.

such as hyperlipidemia, insulin resistance, glucose utilization, and renal function in children as well as adults (170,173,174).

It is regrettable that IGF-1 is available to only a very few of the many patients in need of replacement therapy (185).

PARTIAL GROWTH HORMONE INSENSITIVITY (GHI)

In recent years the possible existence of partial GH insensitivity as one of the causes of so-called idiopathic short stature (ISS) has been raised (186) as children with ISS do not respond to exogenous hGH as well as children with GHD. Goddard et al. (187) found in 14 out of a series of children with ISS, selected because of low GHBP in the presence of normal GH levels, 5 GH receptor mutations. in four patients. One patient was a double heterozygote with a missense mutation in exon 4 (GLU44→Lys) and a missense mutation in exon 6 (Arg161→Cys). The exon 4 mutation was inherited from the father and the exon 6 mutation from the mother. It is of interest that this patient did not have severe growth failure. Three other patients were heterozygotes for a nonsense mutation in exon 5 introducing a premature stop codon (Cys 122 stop) and two other patients were heterozygotes for missense mutations in exon 7 (Arg211→His or GLU 224→ASP), without defects in the other allele.

There is no strong evidence that heterozygous mutations of only one allele cause GH resistance as most children studied by Goddard et al. (187) showed a response to GH therapy. In our cohort of patients with classical LS (50), 1/15 heterozygote males and 10/16 heterozygote females were below the 3rd centile of height (Tanner charts). However, because most belonged to a generation of new immigrants from underprivileged countries, it is possible that the growth failure resulted from environmental circumstances. Some of the short and normal-sized heterozygous of classical LS patients had below normal GHBP values (125).

In conclusion, the clinical and biochemical features of partial GHI have not yet been clearly elucidated (186) and this entity appears to be very rare. Some double heterozygotes for a GH-R mutation have severe GH resistance and the complete LS phenotype (161), although some do not (187). Most heterozygous family members described so far were of normal height.

The Pygmies

The African Pygmies resemble patients with LS (primary GH insensitivity) in several aspects (188). They are short, both at birth and at final height (males: 145–150 cm; females: 130–145 cm) (189). They have full sexual development and normal reproduction. Their serum GH levels are normal and upon stimulation by hypoglycemia or arginine reach levels up to 30 ng/mL and they are hypoglycemia-unresponsive (190). Serum IGF-1 is low (191,192) and does not rise upon short-term hGH administration (192,193), denoting GH resistance. The molecular cause of the GH receptor abnormality in pygmies is still unknown, however, like patients with LS, it was found that they have reduced GHBP (194). Furthermore, it has been shown that both GH and IGF-1 fail to augment colony formation of T-lymphocytes from Efe pygmies (195), denoting hormone resistance in vitro.

The absence of high levels of serum GH in the pygmies may disprove classical GH resistance, as do the low IGF-1 levels preclude IGF-1 resistance. Studies are needed to determine the molecular etiology of these short people.

INSULIN-LIKE GROWTH FACTOR-1 (IGF-1)

Historical Perspective

The IGFs (1 and 2) were identified in 1957 by Salmon and Daughaday (196) and designated sulfation factor by their ability to stimulate ³⁵sulfate incorporation into rat cartilage. Froesch et al. (197) described the nonsuppressible insulin-like activity (NSILA) of two soluble serum components (NSILA I and II). In 1972 the labels “sulfation factor” and “NSILA” were replaced by the term “somatomedin,” denoting a substance under control and mediating the effects of GH (198). In 1976 Rinderknecht and Humbel (199) isolated two active substances from human serum and due to this structural resemblance to proinsulin were renamed “insulin-like growth factor I and II” (IGF-1 and 2). IGF-1 is the mediator of the anabolic and mitogenic activity of GH (200).

Chemical Structure

The IGFs are members of a family of insulin-related peptides, which include relaxin and several peptides isolated from lower invertebrates (201). IGF-1 is a small peptide consisting of 70 amino acids with a molecular weight of 7649 Da (202). Like insulin, IGF-1 has




Fig. 10. The Type 1 IGF receptor gene and mRNA. Adapted with permission from ref. (206).

an A and B chain connected by disulfide bonds. The C-peptide region has 12 amino acids. The structural similarity to insulin explains the ability of IGF-1 to bind (with low affinity) to the insulin receptor.

The IGF-1 Gene

The IGF-1 gene is encoded on the long arm of chromosome 12q23-23 (203,204). The human IGF-1 gene consists of 6 exons including two leader exons and has two promoters (205) (Fig. 10).

INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS (IGFBPs)

The IGFs circulate in plasma 99% complexed to a family of binding proteins that modulate the availability of free IGF-1 to various tissues. There are 6 binding proteins (207), and possibly more (208). In humans almost 80% of circulating IGF-1 is carried by IGFBP-3 a ternary complex consisting of one molecule of IGF-1, one molecule of IGFBP-3, plus a molecule of an 88 Kd protein named acid-labile subunit (ALS) (209). IGFBP-1 is regulated by insulin and IGF-1 (210). IGFBP-3 is controlled mainly by GH but also to some degree by IGF-1 (211). In states of GHD, serum IGFBP-3 is low (212) but IGFBP-1 is elevated (210) due to a negative insulin and IGF-1 feedback mechanism.

The IGF-1 Receptor

The human IGF-1 receptor (Type 1 receptor) is the product of a single-copy gene spanning over 100 Kb of genomic DNA at the end of the long arm of chromosome 15q 25-26 (213). The gene contains 21 exons (Fig. 10) and its organization resembles that of the structurally related insulin receptor (214). The Type-1 IGF-receptor gene is expressed in virtually every tissue and cell type even during embryogenesis (215).

It is of interest that the liver, the organ with the highest levels of IGF-1 ligand expression, exhibits almost undetectable levels of IGF-1 receptor mRNA, possibly due to the downregulation of the receptor by the local production of IGF-1. Like the insulin recep-




Fig. 11. Resemblance between the IGF-1 and insulin receptors.

tor, the Type-1 IGF receptor is a heterotetramer composed of two extracellular-spanning α subunits and transmembrane β subunits. The α subunits have the binding sites for IGF-1 and are linked by disulfide bonds (Fig. 11). The β subunit has a short extracellular domain, a transmembrane, and an intracellular domain. The intracellular part contains a tyrosine kinase domain, which constitutes the signal-transduction mechanism. Similar to the insulin receptor, the IGF-1 receptor undergoes ligand-induced autophosphorylation, mainly on tyrosines 1131, 1135, and 1136 (216). The activated IGF-1 receptor is capable of phosphorylating other tyrosine-containing substrates, such as IRS-1 (insulin receptor substrate 1) and continue a cascade of enzyme activations via PI3-kinase (phosphatidylinositol-3 kinase), Grb2 (growth factor receptor-bound protein 2), Syp (a phosphotyrosine phosphatase), and Nck (an oncogenic protein) (217–219). Another pathway of the activated IGF-1 receptor is phosphorylation of Shc (src homology domain-protein), which associates with Grb2, and activates Raf leading to a cascade of protein kinases including Raf, MAP kinase, 5 G kinase, and others (220).

Physiological Aspects

IGF-1 is secreted by many tissues and the secretory site seems to determine its actions. The majority of IGF-1 is secreted by the liver and by its transport to other tissues, it acts as an endocrine hormone (221). IGF-1 secreted by other tissues (222), such as cartilaginous cells, acts locally in a paracrine fashion (223). It is also assumed that IGF-1 can act in an autocrine manner as an oncogene (224,225).

The role of IGF-1 in the metabolism of many tissues has recently been reviewed (211, 226). Its effect on pre- and postnatal growth of the skeleton, organs, and tissues including the nervous system have been clearly established in man (227) and experimentally in animals, including knockout of the IGF-1 gene (228).

DEFECTS OF THE IGF-1 GENE AND RECEPTOR

Only one patient with a defective IGF-1 gene has been described so far. In 1996 Woods et al. (229) described a very short 15.8-yr-old boy (height 119 cm = -6.9 height SDS). He had a small head circumference, small jaw, hypogonadism, and mental retardation, and severe bilateral sensorineural deafness. He had high-serum hGH (stimulated peaks up to 175 µg/mL; normal IGFBP-3 levels, but undetectable serum IGF-1). DNA analysis revealed deletion of exons 4 and 5 of the IGF-1 gene. One year of treatment with hGH resulted in poor growth, indicating that he was GH-resistant.

IGF-1 Resistance

Very few reports of short children fit this category, and so far no convincing evidence of a true homozygous IGF-1 receptor defect has been reported. Two heterozygous deletions of the distal arms of chromosome 15, the site of the IGF-1 receptor gene in man, have been reported.

Bierich et al. (230) described a very short girl with typical features of LS. Her birth length was 48 cm, she had hypoglycemic episodes, and both her basal GH and IGF-1 were high. In addition there was a 50% reduction of the specific binding of IGF-1 by the patient's fibroblasts. Momoi et al. (231) reported a 14-yr-old dwarfed girl born after 40 wk gestation with a birth length of 43 cm. There is no mention of her appearance but on several occasions her serum GH and IGF-1 were high, the latter reaching values of 4860 U/L. Not consistent with resistance to IGF-1 was the finding that the patient's cultured fibroblast-bound IGF-1 similarly to control cells. A possible etiology of IGF-1 resistance may be the deletion of one copy of the gene encoding the IGF-1 receptor on the long arm of chromosome 15 (232,233).

Diagnostic Hints

Children born very short (≥ -4 SDS height) with decreased postnatal growth who may not present with all the signs of congenital IGF-1 deficiency but who have elevated serum GH levels should be investigated for a possible abnormality in the IGF-1 gene (low to undetectable serum IGF-1) or IGF-1 receptor gene (high serum IGF-1 levels), once a defect in the GH-R has been excluded.

Comment

Experimental animal models such as the IGF-1 gene knockout (228) are helpful in the study of the basic physiological role of IGF-1. A recent report on the selective knockout of the hepatic IGF-1 gene challenges the concept that circulating IGF-1 (originating from the liver) can replace GH for normal postnatal growth (234). However, IGF-1 plays an essential role in GH-induced postnatal growth (235). IGF-1 receptor knockout mice do not survive after birth (228).

Treatment

Patients with IGF-1 gene deletion or gene mutations should be treated by exogenous IGF-1 administration. For potential patients with IGF-1 receptor defects, there are no available treatments.

Table 4
Similarities and Differences Between Patients
with Molecular Defects in the hGH or IGF-1 Genes or Their Receptors (R)

<i>Characteristics</i>	<i>GHRH-R</i>	<i>hGH-I</i>	<i>hGH-I deletion or mutation</i>		<i>Post- hGH-R</i>	<i>IGF-1</i>	<i>IGF-1-R</i>
	<i>gene mutation</i>	<i>gene deletion</i>	<i>GHBP–</i>	<i>GHBP+</i>	<i>mutation GHBP+</i>	<i>gene deletion</i>	
Dwarfism	+	+	+	+	+	+	+
Short at birth	+	+	+	+	+	+	+
Small cranium	+	+	+	+	+	+	+
Acromicria	+	+	+	+	+	+	?
Obesity	±	+	+	+	–	–	+
Small genitalia and testes	+	+	+	+	+	+	?
Serum hGH	↓	↓	↑	↑	↑	↑	↑
Serum IGF-1	↓	v↓	v↓	v↓	v↓	v↓	↑
Serum insulin	↓	↓	↑	↑	N	?	↓

v, very.

GENOTYPE-PHENOTYPE RELATIONSHIP

Patients with genetic abnormalities along the GH axis present a wide spectrum of phenotypic expression (236,237) (Table 4); however, they have in common severe short stature from –3.5 to –10 height SDS below the mean normal (Tanner growth charts). Typical features of the classical LS (50,183) have been described in patients ranging from receptor defects (45,48) to IGF-1 resistance (230). These patients have a small head circumference, a protruding forehead, acromicria, hypogenitalism, and hypogonadism.

Insufficient data is available to explain the variations of expression in the nervous tissue, including psychological maturation (171,238–240), glucose and adipose tissue metabolism, and so forth (113,114). Some differences in the latter may be explained by the absence or presence of GH signal transmission in instances of mutations downstream of the GH-R, thus permitting some non-IGF-1-dependent actions. It was observed that there are slight differences between the height of GHBP- positive and GHBP-negative patients with LS, the former being slightly less short (175,241,242). As more molecular data becomes available both from patients and their family members, a better understanding of variations in the phenotypic expression of molecular defects along the GH axis will become available.

ACKNOWLEDGMENT

Thanks are due to Mrs. Gila Waichman for her invaluable technical assistance in the preparation of this chapter.

REFERENCES

1. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. *Endocrinology* 1984;115:1952–1957.
2. Devesa J, Lima L, Tresquieres AF. Neuroendocrine control of growth hormone secretion in humans. *Trends Endocrinol Metab* 1992;3:175–183.
3. Reichlin, S. Somatostatin. *N Engl J Med* 1983;309:1495–1501.

4. Gil-Ad I, Koch Y, Silbergeld A, Dickerman Z, Kaplan B, Weizman A, Laron Z. Differential effect of insulin-like growth factor I (IGF-1) and growth hormone (GH) on hypothalamic regulation of GH secretion in the rat. *J Endocrinol Invest* 1996;19:542–547.
5. Jaffe CA, Ho, PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. *J Clin Endocrinol Metab* 1993;77:1641–1647.
6. Ghigo E, Boghen M, Casanueva FF, Dieguez C, eds. *Growth Hormone Secretagogues. Basic Findings and Clinical Implications*. Elsevier, Amsterdam, 1994, pp. 325.
7. Howard AD, Feighner SD, Cully DF, Arena JP, Liberatore PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. *Science* 1996;273:974–977.
8. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999;402:656–660.
9. Wajnrajch MP, Ten IS, Gertner JM, Leibel RL. Genomic organization of the human GHRELIN gene. *J Endocrine Genet* 2000;1:231–233.
10. Folowaczny C, Chang JK, Tschöp M. Ghrelin and motilin: two sides of one coin? *Eur J Endocrinol* 2001;144:R1–R3.
11. Tomasseto C, Karam S, Riberias S, Masson R, Lefebvre O, Staub A, et al. Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. *Gastroenterology* 2000;119:395–405.
12. Feighner SD, Tan SP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, et al. Receptor for motilin identified in the human gastrointestinal system. *Science* 1999;284:2184–2188.
13. Itoh Z. Motilin and clinical application. *Peptides* 1997;18:693–698.
14. Peino R, Baldelli R, Rodriguez-Garcia J, Rodriguez-Segade S, Kojima M, Kangawa K, et al. Ghrelin-induced growth hormone secretion in humans. *Eur J Endocrinol* 2000;143:R11–R14.
15. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. *Gastroenterology* 2001;120:337–345.
16. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. *Nature* 2000;407:908–913.
17. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyazawa F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. *Diabetes* 2001;50:227–232.
18. Tschöp M, Wawarta RL, Friedrich S, Bidlingmaier M, Landrag R, Folwaczny C. Post-prandial decrease of circulating human Ghrelin levels. *J Endocrinol Invest* 2001;24:RC19–RC21.
19. Gualillo O, Caminos JE, Blanco M, Garcia-Caballero T, Kojima M, Kangawa K, et al. Ghrelin, a novel placental-derived hormone. *Endocrinology* 2001;142:788–794.
20. Reichlin S. Growth hormone content of pituitaries in rats with hypothalamic lesions. *Endocrinology* 1961;69:225–230.
21. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. *Science* 1981;218:585–587.
22. Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. *Biochemistry* 1982;21:6037–6040.
23. Campbell RM, Scanes CG. Evolution of the growth hormone-releasing factor (GRF) family of peptides. *Growth Regul* 1992;2:175–191.
24. Hofman PL, Pescovitz OH. Growth hormone releasing hormone: biological and molecular aspects. In: Handwerger S, ed. *Molecular and Cellular Pediatric Endocrinology*. Humana Press, Totowa, NJ, 1999, pp. 85–112.
25. Mayo KE, Cerelli GM, Lebo RV, Bruce BD, Rosenfeld MG, Evans RM. Gene encoding human growth hormone-releasing factor precursor: structure, sequence, and chromosomal assignment. *Proc Natl Acad Sci USA* 1985;82:63–67.
26. Perez Jurado, LA, Phillips JA III, Summar ML, Mao J, Weber JL, Schaefer FV, et al. Genetic mapping of the human growth hormone-releasing factor gene (GHRF) using two intragenic polymorphisms detected by PCR amplification. *Genomics* 1994;20:132–134.
27. Bosman FT, Van Assche C, Nieuwenhuysen Kruseman AC, Jackson S, Lowry PJ. Growth hormone releasing factor (GRF) immunoreactivity in human and rat gastrointestinal tract and pancreas. *J Histochem Cytochem* 1984;32:1139–1144.
28. Berry SA, Srivastava CH, Rubin LR, Phipps WR, Pescovitz OH. Growth hormone-releasing hormone-like messenger ribonucleic acid and immunoreactive peptide are present in human testis and placenta. *J Clin Endocrinol Metab* 1992;75:281–284.

29. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. *Nature* 1982;300:276–278.
30. Asa SL, Kovacs J, Thorner MO, Leong DA, Rivier J, Vale W. Immunohistological localization of growth hormone-releasing hormone in human tumors. *J Clin Endocrinol Metab* 1985;60:423–427.
31. Guillemin R, Zeytin F, Ling N, Bohlen P, Esch F, Brazeau P, et al. Growth hormone-releasing factor: chemistry and physiology (41813). *Proc Soc Exp Biol Med* 1984;175:407–413.
32. Laron Z. Usefulness of the growth hormone-releasing hormone test regardless of which fragment is used (GHRH 1-44, 1-40 or 1-29). *Isr J Med Sci* 1991;27:343–345.
33. Schriock EA, Lustig RH, Rosenthal SM, Kaplan SL, Grumbach MM. Effect of growth hormone (GH)-releasing hormone (GRH) on plasma GH in relation to magnitude and duration of GH deficiency in 26 children and adults with isolated GH deficiency or multiple pituitary hormone deficiencies: evidence for hypothalamic GRH deficiency. *J Clin Endocrinol Metab* 1984;58:1043–1049.
34. Pertzelan A, Keret R, Bauman B, Ben-Zeev Z, Olsen DB, Comaru-Schally AM, et al. Plasma GH response to synthetic GH-RH 1-44 in 52 children and adults with GH deficiency of various etiologies. *Horm Res* 1985;22:24–31.
35. Keret R, Josefsberg Z, Kinarti H, Silbergeld A, Szoke B, Schally AV, Laron Z. Discrimination between growth hormone (GH) deficiency of hypothalamic or pituitary origin: an aid in selecting patients for GH-releasing hormone (RH) prolonged therapy. *Isr J Med Sci* 1988;24:207–211.
36. Barinaga M, Yamamoto G, Rivier C, Vale W, Evans R, Rosenfeld MG. Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor. *Nature* 1983;306:84–85.
37. Billestrup N, Swanson LW, Vale W. Growth hormone-releasing hormone stimulates proliferation of somatotrophs *in vitro*. *Proc Natl Acad Sci USA* 1986;83:6854–6857.
38. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. *Mol Endocrinol* 1992;6:1734–1744.
39. Gaylinn BD, Harrison JK, Zysk JR, Lyons CE, Lynch KR, Thorner MO. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. *Mol Endocrinol* 1993;7:77–84.
40. Godfrey P, Rahal JO, Beamer WC, Copeland NH, Jenkins NA, Mayo KE. GHRH receptor of *little* mice contains a missense mutation in the extracellular domain that disrupts receptor function. *Nat Genet* 1993;4:227–232.
41. Labrie F, Gagne B, Lefevre G. Growth hormone-releasing factor stimulates adenylate cyclase activity in the anterior pituitary gland. *Life Sci* 1983;33:2229–2233.
42. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. *Mol Endocrinol* 1992;6:1734–1744.
43. Vamvakopoulos NC, Kunz J, Olberding U, Scherer SW, Sioutopoulou TO, Schneider V, et al. Mapping the human growth hormone-releasing hormone receptor (GHRHR) gene to the short arm of chromosome 7 (7p13-p21) near the epidermal growth factor receptor (EGFR) gene. *Genomics* 1994;20:338–340.
44. Wajnrajch MP, Chua SC, Green ED, Leibel RL. Human growth hormone-releasing hormone receptor (GHRHR) maps to a YAC at chromosome 7p15. *Mamm Genet* 1994;5:595.
45. Wajnrajch MP, Gertner JM, Harbison MD, Chua SC Jr, Leibel RL. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the *little (lit)* mouse. *Nature Genet* 1996;12:88–90.
46. Maheshwari HG, Silverman BL, Dupuis J, Baumann G. Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone releasing hormone receptor. Dwarfism of Sindh. *J Clin Endocrinol Metab* 1998;83:4065–4074.
47. Netchine I, Talon P, Dastot F, Vitaux F, Goossens M, Amselem S. Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. *J Clin Endocrinol Metab* 1998;83:432–436.
48. Salvatori R, Hayashida CY, Aguilar-Oliveira MH, Phillips JA III, Souza AHO, Gondo RG, et al. Familial dwarfism due to a novel mutation in the growth hormone-releasing hormone receptor gene. *J Clin Endocrinol Metab* 1999;84:914–923.
49. Laron Z. Deficiencies of growth hormone and somatomedins in man. In: Cohen MP, Foa PP, eds. *Special Topics in Endocrinology and Metabolism*, vol. 5. Alan R. Liss, Inc., New York, 1983, pp. 149–199.
50. Laron Z. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). *J Pediatr Endocrinol Metab* 1999;12:231–249.
51. Li CH, Papapkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. *Science* 1956;124:1293–1294.

52. Miller WL, Eberhart NL. Structure and evaluation of the growth hormone gene family. *Endocr Rev* 1983;4:97–130.
53. Laron Z, Mannheimer S. Measurement of human growth hormone. Description of the method and its clinical applications. *Isr J Med Sci* 1966;2:115–119.
54. Schechter J, Kovacs K, Rimoin D. Isolated growth hormone deficiency: immunocytochemistry. *J Clin Endocrinol Metab* 1984;59:798–800.
55. Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen G. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. *J Clin Endocrinol Metab* 1988;66:1171–1180.
56. George DL, Phillips JA III, Francke U, Seeburg PH. The genes for growth hormone and chorionic somatomammotropin are on the long arm of human chromosome 17 in region q21-qter. *Hum Genet* 1981;57:138–141.
57. MacLeod JN, Lee AK, Liebhaber SA, Cooke NE. Developmental control and alternative splicing of the placentally expressed transcripts from the human growth hormone gene cluster. *J Biol Chem* 1992; 267:14,219–14,226.
58. Parks JS, Nielsen PV, Sexton LA, Jorgensen EH. An effect of gene dosage on production of human chorionic somatomammotropin. *J Clin Endocrinol Metab* 1985;50:994–997.
59. Lewis UJ, Singh RNP, Tutwiler GH, Siegel MB, Van der Laan EF, Van der Laan WP. Human growth hormone: a complex of proteins. *Rec Progr Horm Res* 1980;36:477–508.
60. Lewis UJ, Bonewald LF, Lewis LJ. The 20,000 dalton variant of human growth hormone: location of the amino acid deletions. *Biochem Biophys Res Comm* 1980;92:511–516.
61. Cooke NE, Ray J, Watson MA, Ester PA, Kuo BA, Liebhaber SA. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. *J. Clin Invest* 1988;82:270–275.
62. Culler FL, Kaufman S, Frigeri LG, Jones KL. Comparison of the acute metabolic effects of 22,000-dalton and 20,000-dalton growth hormone in human subjects. *Horm Metab Res* 1988;20:107–109.
63. Rowlinson SW, Waters MJ, Lewis UJ, Barnard R. Human growth hormone fragments 1-43 and 44-191: *in vitro* somatogenic activity and receptor binding characteristics in human and nonprimate systems. *Endocrinology* 1996;137:90–95.
64. Ray J, Jones BK, Liebhaber SA, Cooke NE. Glycosylated human growth hormone variant. *Endocrinology* 1989;125:566–568.
65. Kuhlmann BV, Mullis PE. Genetics of the growth hormone axis. *J Pediatr Endocrinol Metab* 1997;10: 161–174.
66. Illig R, Prader A, Ferrandez M, Zachman M. Hereditary prenatal growth hormone deficiency with increased tendency to growth hormone antibody formation. A type of isolated growth hormone deficiency. *Acta Paediatr Scand* 1971;60(Suppl):607.
67. Phillips JA III, Hjelle B, Seeburg PH, Zachmann M. Molecular basis for familial isolated growth hormone deficiency. *Proc Natl Acad Sci USA* 1981;78:6372–6375.
68. Nishi Y, Aihara K, Usui T, Phillips JA III, Mallonee RL, Migeon CJ. Isolated growth hormone deficiency type IA in a Japanese family. *J Pediatr* 1984;104:885–889.
69. Rivarola MA, Phillips JA III, Migeon CJ, Heinrich JJ, Hjelle BL. Phenotypic heterogeneity in familial isolated growth hormone deficiency type I-A. *J Clin Endocrinol Metab* 1984;59:34–40.
70. Laron Z, Kelijman M, Pertzalan A, Keret R, Shoffner JM, Parks JS. Human growth hormone gene deletion without antibody formation or growth arrest during treatment: a new disease entity. *Isr J Med Sci* 1985;21:999–1006.
71. Braga S, Phillips JA III, Joss E, Schwarz H, Zuppinger K. Familial growth hormone deficiency resulting from a 7.6 kb deletion within the growth hormone gene cluster. *Am J Med Genet* 1986;25:443–452.
72. Frisch H, Phillips JA III. Growth hormone deficiency due to GH-N gene deletion in an Austrian family. *Acta Endocrinol (Copenh)* 1986;27(Suppl):107–112.
73. Goossens M, Brauner R, Czernichow P, Duquesnoy P, Rappaport R. Isolated growth hormone (GH) deficiency type IA associated with a double deletion in the human GH gene cluster. *J Clin Endocrinol Metab* 1986;62:712–716.
74. Matsuda I, Hata A, Jinno Y, Endo F, Akaboshi I, Nishi Y, et al. Heterogeneous phenotypes of Japanese cases with a growth hormone gene deletion. *Jpn J Human Genet* 1987;32:227–235.
75. Vnencak-Jones CL, Phillips JA III, Chen EY, Seeburg PH. Molecular basis of human growth hormone gene deletion. *Proc Natl Acad Sci USA* 1988;85:5615–5619.

76. He YA, Chen SS, Wang YX, Lin XY, Wang DF. A Chinese familial growth hormone deficiency with a deletion of 7.1 kb of DNA. *J Med Genet* 1990;27:151–154.
77. Duquesnoy P, Amsellem S, Gourmelen M, Le Bouc Y, Goossens M. A frame shift mutation causing isolated growth hormone deficiency type IA. *Am J Hum Genet* 1990;47:A110.
78. Nishi Y, Masuda H, Nishimura S, Kihara M, Suwa S, Tachibana K, et al. Isolated human deficiency due to the hGH-I gene deletion with (type IA) and without (the I Israeli-type) hGH antibody formation during hGH therapy. *Acta Endocrinol (Copenh)* 1990;122:267–271.
79. Akinci A, Kanaka C, Eble A, Akar N, Vidialisan S, Mullis PE. Isolated growth hormone (GH) deficiency type IA associated with a 45-kilobase gene deletion within the human GH gene cluster. *J Clin Endocrinol Metab* 1992;75:437–441.
80. Kamijo T, Phillips JA III. Detection of molecular heterogeneity in GH-I gene deletions by analysis of polymerase chain reaction amplification products. *J Clin Endocrinol Metab* 1992;75:786–789.
81. Cogan JD, Phillips JA III, Sakati N, Frisch H, Schober E, Milner RDG. Heterogenous growth hormone (GH) gene mutations in familial GH deficiency. *J Clin Endocrinol Metab* 1993;76:1124–1128.
82. Mullis PE, Akinci A, Kanaka Ch, Eble A, Brook CGD. Prevalence of human growth hormone-I gene deletions among patients with isolated growth hormone deficiency from different populations. *Pediatr Res* 1992;31:532–534.
83. Parks JS, Meacham LR, McKean MC, Keret R, Josefsberg Z, Laron Z. Growth hormone (GH) gene deletion is the most common cause of severe GH deficiency among oriental Jewish children. *Pediatr Res* 1989;25:90A.
84. Parks JS, Faase E. GH and GH-receptor genes. In: Merimee TJ, Laron Z, eds. *Growth Hormone, IGF-1 and Growth: New Views of Old Concepts*. Modern Endocrinology and Diabetes, vol. 4. Freund Publishing House Ltd., London, Tel Aviv, 1996, pp. 23–43.
85. Cogan JD, Phillips JA III, Schenkman SS, Milner RDG, Sakati N. Familial growth hormone deficiency: a model of dominant and recessive mutations affecting a monomeric protein. *J Clin Endocrinol Metab* 1994;79:1261–1265.
86. Igarashi Y, Ogawa M, Kamijo T, Iwatani N, Nishi Y, Kohno H, et al. A new mutation causing inherited growth hormone deficiency: a compound heterozygote of a 6.7 kb deletion and a two base deletion in the third exon of the GH-I gene. *Hum Mol Genet* 1993;2:1073–1074.
87. Nishi Y, Ogawa M, Kamijo T, Igarashi Y, Iwatani N, Kohno H, et al. A case of isolated growth hormone (GH) deficiency with compound heterozygous abnormality at the GH-I gene locus. *J Pediatric Endocrinol Metab* 1997;10:73–76.
88. De Luca F, Duquesnoy P, Arrigo T, Lombardo F, Goossens M. Long-lasting catch-up growth under bio-methionyl growth hormone treatment in an infant with isolated growth hormone deficiency Type 1A. *Acta Paediatr Scand* 1991;80:1235–1240.
89. Arnhold IJP, Oliveira SB, Osorio MGF, Mendonca BB. Insulin-like growth factor-1 treatment in two children with growth hormone gene deletions. *J Pediatric Endocrinol Metab* 1999;12:499–506.
90. Phillips JA III, Cogan JD. Genetic basis of endocrine disease. Molecular basis of familial human growth hormone deficiency. *J Clin Endocrinol Metab* 1994;78:11–16.
91. Abdul-Latif H, Leiberman E, Brown MR, Carmi R, Parks JS. Growth hormone deficiency type IB caused by cryptic splicing of the GH-I gene. *J Pediatric Endocrinol Metab* 2000;13:21–38.
92. Jaber L, Bailey-Wilson JE, Haj-Yehia M, Hernandez J, Shohat M. Consanguineous matings in an Israeli-Arab community. *Arch Pediatr Adolesc Med* 1994;148:412–415.
93. Saitoh H, Fukushima T, Kamoda T, Tanae A, Kamijo T, Yamamoto M, et al. A Japanese family with autosomal dominant growth hormone deficiency. *Eur J Pediatr* 1999;158:624–627.
94. Missarelli C, Herrera L, Mericq V, Carvallo P. Two different 5' splice site mutations in the growth hormone gene causing autosomal dominant growth hormone deficiency. *Hum Genet* 1997;101:113–117.
95. Kamijo T, Hayashi Y, Shimatsu S, Kinoshita E, Yoshimoto M, Ogawa M, Seo H. Mutations in intron 3 of GH-I gene associated with isolated GH deficiency type II in three Japanese families. *Clin Endocrinol (Oxford)* 1999;51:355–360.
96. Hayashi Y, Yamamoto M, Ohmori S, Kamijo T, Ogawa M, Seo H. Inhibition of growth hormone secretion by a mutant *GH-I* gene product in neuroendocrine cells containing secretory granules: an implication for isolated growth hormone deficiency. *J Clin Endocrinol Metab* 1999;84:2134–2139.
97. Hayashi Y, Kamijo T, Yamamoto M, Ohmori S, Phillips JA III, Ogawa M, et al. A novel mutation at the donor splice site of intron 3 of the *GH-I* gene in a patient with isolated growth hormone deficiency. *GH IGF Res* 1999;9:434–437.

98. Fleisher TA, White RM, Broder S. X-linked hypogammaglobulinemia and isolated growth hormone deficiency. *N Engl J Med* 1980;302:1429–1434.
99. Tang MLK, Kemp AS. Growth hormone deficiency and combined immunodeficiency. *Arch Dis Child* 1993;68:231–232.
100. Phillips JA III. Regulation and defects in expression of growth hormone genes. In: Isaksoon O, Binder C, Hall K, Hokfelt B, eds. *Growth Hormone. Basic and Clinical Aspects*. International Congress Series. Excerpta Medica, Amsterdam, 1987, pp. 11–27.
101. Conley ME, Burks AW, Herrod HG, Puck JM. Molecular analysis of X-linked agammaglobulinemia with growth hormone deficiency. *J Pediatr* 1991;119:392–397.
102. Ogata T, Petit C, Rappold G, Matsuo N, Matsumoto T, Goodfellow P. Chromosomal localization of a pseudoautosomal growth gene(s). *J Med Genet* 1992;29:624–628.
103. Yokoyawa Y, Narahara K, Tsuji K, Moriwake T, Kanzaki S, Murakami M, et al. Growth hormone deficiency and empty sella syndrome in a boy with dup(X)-q13.3 → q21.2). *Am J Med Genet* 1992;42:660–664.
104. Weinzimmer SA, McDonald-McGinn DM, Driscoll DA, Emanuel BS, Zackai EH, Moshang T Jr. Growth hormone deficiency in patients with a 22q11.2 deletion: expanding the phenotype. *Pediatrics* 1998;101:929–932.
105. Wagner JK, Eble A, Hindmarsh PC, Mullis PE. Prevalence of human *GH-I* gene alterations in patients with isolated growth hormone deficiency. *Pediatr Res* 1998;43:105–110.
106. Takahashi Y, Kaji H, Okimura Y, Goji K, Abe H, Chihara K. Brief report: short stature caused by a mutant growth hormone. *N Engl J Med* 1996;334:432–436.
107. Takahashi Y, Shirono H, Arisaka O, Takahashi K, Yagi T, Koga J, et al. Biologically inactive growth hormone caused by an amino acid sub-situation. *J Clin Invest* 1997;100:1159–1165.
108. Takahashi Y, Chihara K. Short stature by mutant growth hormones. *GH IGF Res* 1999;9(Suppl B):37–41.
109. Kelly PA, Goujon L, Sotiropoulos A, Dinerstein H, Esposito N, Edery M, et al. The GH receptor and signal transduction. *Horm Res* 1994;42:133–139.
110. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. *Nature* 1987;330:537–543.
111. Godowski PJ, Leung DW, Meacham LR, Galgagni JP, Hellmiss R, Keret R, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism. *Proc Natl Acad Sci USA* 1989;86:8083–8088.
112. Barton DE, Foellmer BE, Wopod WI, Francke U. Chromosome mapping of the growth hormone receptor gene in man and mouse. *Cytogenet Cell Genet* 1989;50:137–141.
113. Cunningham BC, Ultsch M, de Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. *Science* 1991;254:821–825.
114. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science* 1992;255:306–312.
115. Bass SH, Mulkerrin MG, Wells JA. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. *Proc Natl Acad Sci USA* 1991;88:4498–4502.
116. Souza SC, Frick GP, Wang X, Kopchick JJ, Lobo RB, Goodman HM. A single arginine residue determines species specificity of the human growth hormone receptor. *Proc Natl Acad Sci USA* 1995;92:959–963.
117. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. *Cell* 1993;74:237–244.
118. Smit LS, Myer DJ, Billestrup N, Norstedt G, Schwartz J, Carter-Su C. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. *Mol Endocrinol* 1996;10:519–533.
119. Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. *J Clin Invest* 1986;77:1817–1823.
120. Baumann G, Stolar MN, Amburn K, Barsano CP, DeVries BC. A specific GH-binding protein in human plasma: initial characterization. *J Clin Endocrinol Metab* 1986;62:134–141.
121. Silbergeld A, Lazar L, Erster B, Keret R, Tepper R, Laron Z. Serum growth hormone binding protein activity in healthy neonates, children and young adults correlation with age, height and weight. *Clin Endocrinol* 1989;31:295–303.

122. Sotiropoulos A, Goujon L, Simonin G, Kelly PA, Postel-Vinay MC, Finidori J. Evidence for genetation of the growth hormone-binding protein through proteolysis of the growth hormone membrane receptor. *Endocrinology* 1993;132:1863–1865.
123. Silbergeld A, Keret R, Selman-Almonte A, Klinger B, Laron Z. Serum growth hormone binding protein in Laron syndrome patients and their relatives. In: Laron Z, Parks JS, eds. *Lessons from Laron Syndrome (LS) 1966–1992*. Pediatric and Adolescent Endocrinology, vol. 24. Karger, Basel, New York, 1993, pp. 153–159.
124. Laron Z. Prismatic cases: Laron Syndrome (primary growth hormone resistance). From patient to laboratory to patient. *J Clin Endocrinol Metab* 1995;80:1526–1573.
125. Laron Z, Klinger B, Erster B, Silbergeld A. Serum GH binding protein activity identifies the heterozygous carriers for Laron type dwarfism. *Acta Endocrinol* 1989;121:603–608.
126. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? *Isr J Med Sci* 1966;2:152–155.
127. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. *Isr J Med Sci* 1968;4:883–894.
128. Daughaday WH, Laron Z, Pertzelan A, Heins JN. Defective sulfation factor generation: a possible etiological link in dwarfism. *Trans Assoc Am Phys* 1969;82:129–138.
129. Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses. *J Clin Endocrinol Metab* 1971;33:332–342.
130. Eshet R, Laron Z, Brown M, Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. *J Clin Endocrinol Metab* 1973;37:819–821.
131. Eshet R, Laron Z, Brown M, Arnon R. Immunological behaviour of hGH from plasma of patients with familial dwarfism and high IR-hGH in a radioimmunoassay system using the cross-reaction between hGH and HCS. *Horm Metab Res* 1974;6:79–81.
132. Jacobs LS, Sneid DS, Garland JT, Laron Z, Daughaday WH. Receptor-active growth hormone in Laron dwarfism. *J Clin Endocrinol Metab* 1976;43:403–407.
133. Eshet R, Peleg S, Josefsberg Z, Laron Z. Characterization of hGH from patients with LTD by a human liver radioreceptor assay (RRA) (abstract). *Pediatr Res* 1981;15:89.
134. Eshet R, Laron Z, Pertzelan A, Dintzman M. Defect of human growth hormone in the liver of two patients with Laron type dwarfism. *Isr J Med Sci* 1984;20:8–11.
135. Rosenbloom AL, Guevarra-Aguirre J, Rosenfeld RG, Francke U. Growth hormone receptor deficiency in Ecuador. *J Clin Endocrinol Metab* 1999;84:4436–4443.
136. Laron Z. Laron Syndrome: from description to therapy. *Endocrinologist* 1993;3:21–28.
137. Yordam N, Kandemir N, Erkul I, Kurdoglu S, Hatun S. Review of Turkish patients with growth hormone insensitivity (Laron type). *Eur J Endocrinol* 1995;133:539–542.
138. Razzaghy-Azar M. Laron Syndrome: a review of 8 Iranian patients with Laron syndrome. In: Laron Z, Parks JS, eds. *Lessons from Laron Syndrome (LS) 1966–1992*. Pediatric and Adolescent Endocrinology, vol. 24. Karger, Basel-New York, 1993, pp. 93–100.
139. Desai MP, Colaco P, Choksi CS, Sanghavi KP, Ambedkar MC, Vaz FEE. Endogenous growth hormone nonresponsive dwarfism in Indian children. In: Laron Z, Parks JS, eds. *Lessons from Laron Syndrome (LS) 1966–1992*. Pediatric and Adolescent Endocrinology, vol. 24. Karger, Basel-New York, 1993, pp. 81–92.
140. Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, et al. Clinical, biochemical and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). *J Clin Endocrinol Metab* 1997;82:444–451.
141. Laron Z. Laron type dwarfism (hereditary somatomedin deficiency): a review. In: Frick P, Von Harnack GA, Kochsiek GA, Prader A, eds. *Advances in Internal Medicine and Pediatrics*. Springer-Verlag, Berlin, 1984, pp. 117–150.
142. Rosenbloom AL, Guevara-Aguirre J. Lessons from the genetics of Laron Syndrome. *TEM* 1998;9:276–283.
143. Laron Z. Laron syndrome: primary growth hormone resistance. In: Jameson JL, ed. *Hormone Resistance Syndromes*. Contemporary Endocrinology, vol. 2. Humana Press, Totowa, NJ, 1999, pp. 17–37.
144. Tiulpakov AN, Orlovsky IV, Kalintchenko NU, Lonina DA, Kalesnikova GS, Peterkova VA, et al. Growth hormone insensitivity (Laron Syndrome) in a Russian girl of Slavic origin caused by a common mutation of the GH receptor gene. *J Endocrine Genet* 1999;1:95–100.

145. Pertzelan A, Adam A, Laron Z. Genetic aspects of pituitary dwarfism due to absence of biological activity of growth hormone. *Isr J Med Sci* 1968;4:895–900.
146. Laron Z, Pertzelan A, Karp M, Keret R, Eshet R, Silbergeld A. Laron syndrome: a unique model of IGF-1 deficiency. In: Laron Z, Parks JS, eds. *Lessons from Laron Syndrome (LS) 1966–1992. Pediatric and Adolescent Endocrinology*, vol. 24. Karger, Basel-New York, 1993, pp. 3–23.
147. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goossens M. Laron dwarfism and mutations of the growth hormone-receptor gene. *N Engl J Med* 1989;321:989–995.
148. Amselem S, Sobrier ML, Duquesnoy P, Rappaport R, Postel-Vinay MS, Gourmelen M, et al. Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism. *J Clin Invest* 1991;87:1098–1102.
149. Meacham WR, Brown MR, Murphy TL, Keret R, Silbergeld A, Laron Z, Parks JS. Characterization of a noncontiguous gene deletion of the growth hormone receptor in Laron's syndrome. *J Clin Endocrinol Metab* 1993;77:1379–1383.
150. Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, Amselem S. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. *J Clin Endocrinol Metab* 1997;82:435–437.
151. Berg MA, Peoples R, Perez-Jurado L, Guevara-Aguirre J, Rosenbloom AL, Laron Z, et al. Receptor mutations and haplotypes in growth hormone receptor deficiency: a global survey and identification of the Ecuadorean E180splice mutation in an oriental Jewish patient. *Acta Paediatr* 1994;399(Suppl): 112–114.
152. Amselem S, Duquesnoy P, Duriez B, Dastot F, Sobrier ML, Valleix S. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. *Hum Mol Genet* 1993;2:355–359.
153. Counts DR, Cutler GB. Growth hormone insensitivity syndrome due to point deletion and frame shift in the growth hormone receptor. *J Clin Endocrinol Metab* 1995;80:1978–1981.
154. Berg MA, Argente J, Chernauek S, Gracia R, Guevara-Aguirre J, Hopp M, et al. Diverse growth hormone receptor gene mutations in Laron syndrome. *Am J Hum Genet* 1993;52:998–1005.
155. Berg MA, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG, Francke U. Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. *Hum Mutation* 1992;1:124–134.
156. Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron Syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. *J Pediatr Endocrinol Metab* 1997; 10:265–274.
157. Woods KA, Fraser NC, Postel-Vinay MC, Dusquenoy P, Savage MO, Clark AJL. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. *J Clin Endocrinol Metab* 1996;81:1686–1690.
158. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. *EMBO J* 1994;13:1386–1395.
159. Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. *J Clin Endocrinol Metab* 1993;76:54–59.
160. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. *Nature Genet* 1997;16:13–14.
161. Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Hiromi A, Chihara K. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. *J Clin Endocrinol Metab* 1998;83:531–537.
162. Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, Waters MJ. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-1 and luteinizing hormone-releasing hormone analogue. *J Clin Endocrinol Metab* 1998;83:2554–2561.
163. Laron Z, Klinger B, Eshet R, Kanety H, Karasik A, Silbergeld A. Laron Syndrome due to a post-receptor defect: response to IGF-1 treatment. *Isr J Med Sci* 1993;29:757–763.
164. Freeth JS, Ayling RM, Whatmore AJ, Towner P, Price DA, Norman MR, Clayton PE. Human skin fibroblasts as a model of growth hormone action in growth hormone receptor-positive Laron's Syndrome. *Endocrinology* 1997;138:55–61.

165. Freeth JS, Silva CM, Whatmore AJ, Clayton PE. Activation of the signal transducers and activators of transcription signaling pathway by growth hormone (GH) in skin fibroblasts from normal and GH binding protein-positive Laron Syndrome children. *Endocrinology* 1998;139:20–28.
166. Woods KA, Savage MO. Laron syndrome: typical and atypical forms. *Bailliere's Clin Endocrinol Metab* 1996;10:371–387.
167. Laron Z, Klinger B, Grunebaum M. Laron type dwarfism. Special feature: picture of the month. *Am J Dis Child* 1991;145:473–474.
168. Laron Z, Sarel R. Penis and testicular size in patients with growth hormone insufficiency. *Acta Endocrinol* 1970;63:625–633.
169. Arad I, Laron Z. Standards for upper/lower body segment ratio/sitting height: subischial leg length from birth to 18 years in girls and boys. In: *Proceedings 1st International Congress of Auxology, Rome, 1977 Milan, Centro Auxologia Italiano di Piancavallo, 1979*, pp. 159–164.
170. Laron Z, Klinger B. IGF-1 treatment of adult patients with Laron syndrome. *Clin Endocrinol* 1994;41:631–638.
171. Galatzer A, Aran O, Nagelberg N, Rubitzek J, Laron Z. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, eds. *Lessons from Laron Syndrome (LS) 1966–1992. Pediatric and Adolescent Endocrinology*, vol. 24. Karger, Basel-New York, 1993, pp. 53–60.
172. Laron Z, Sarel R, Pertzalan A. Puberty in Laron type dwarfism. *Eur J Pediatr* 1980;134:79–83.
173. Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. *Horm Res* 1993;40:16–22.
174. Laron Z, Avitzur Y, Klinger B. Insulin resistance in Laron Syndrome (primary insulin-like growth factor-1 [IGF-1] deficiency) and effect of IGF-1 replacement therapy. *J Pediatr Endocrinol Metab* 1997;10(Suppl 1):105–115.
175. Laron Z, Desai M, Silbergeld A. Girls with Laron syndrome having positive growth hormone binding protein (GHBP) are less retarded in height than those lacking GHBP. *J Pediatr Endocrinol Metab* 1997;10:305–307.
176. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, Underwood L. Classification of growth hormone insensitivity syndrome. *J Pediatr* 1993;122:241.
177. Rosenbloom AL, Martinez V, Kranzier JH, Bachrach LK, Rosenfeld RG, Guevarra-Aguire J. Natural history of growth hormone receptor deficiency. *Acta Paediatr* 1999;428(Suppl):153–156.
178. Laron Z, Klinger B, Erster B, Anin S. Effect of acute administration of insulin-like growth factor in patients with Laron-type dwarfism. *Lancet* 1988;ii:1170–1172.
179. Azcona C, Preece MA, Rose SJ, Fraser N, Rappaport R, Ranke MB, Savage MO. Growth response to rhIGF-1 80 µg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. *Clin Endocrinol* 1999;51:787–792.
180. Backeljauw PF, Underwood LE and the GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-1 in children with growth hormone insensitivity syndrome: a Clinical Research Center study. *J Clin Endocrinol Metab* 1996;81:3312–3317.
181. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor-1 in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. *J Clin Endocrinol Metab* 1997;82:629–633.
182. Klinger B, Laron Z. Three year IGF-1 treatment of children with Laron Syndrome. *J Pediatr Endocrinol Metab* 1995;8:149–158.
183. Laron Z. The essential role of IGF-1. Lessons from the long-term study and treatment of children and adults with Laron syndrome. *J Clin Endocrinol Metab* 1999;84:4397–4404.
184. Laron Z, Klinger B. Comparison of the growth-promoting effects of insulin-like growth factor I and growth hormone in the early years of life. *Acta Paediatr* 2000;88:38–41.
185. Laron Z. Clinical use of insulin-like growth factor-1—Yes or no? (Leading Article). *Paediatr Drugs* 1999;1:155–159.
186. Johnston LB, Savage MO. Partial growth hormone insensitivity. *J Pediatr Endocrinol Metab* 1999;12(Suppl 1):251–257.
187. Goddard AD, Covello R, Luoh S-M, Clackson T, Attie KM, Gesundheit N, et al. Growth hormone receptor mutations in idiopathic short stature. *N Engl J Med* 1995;333:1093–1098.
188. Merimee TJ, Laron Z. The Pygmy. In: *Growth Hormone, IGF-1 and Growth: New Views of Old Concepts*. Freund Publishing House Ltd., London, 1996, pp. 217–240.

189. Cavalli-Sforza LL. Ed. *Anthropometric Data in African Pygmies*. Academic Press, New York, 1986, pp. 81–94.
190. Merimee TJ, Rimoin DL, Cavalli-Sforza LL. Metabolic studies in the African pygmy. *J Clin Invest* 1972;51:395–401.
191. Merimee TJ. Growth hormone and IGF abnormalities of the African pygmy. In: LeRoith D, Raizada M, eds. *Molecular and Cellular Biology of Insulin Like Growth Factors and Their Receptors*. Plenum Press, New York, 1989, pp. 73–81.
192. Merimee TJ, Zapf J, Froesch ER. Insulin like growth factors in pygmies and subjects with the pygmy trait. *J Clin Endocrinol Metab* 1982;55:1081–1088.
193. Rimoin DL, Merimee TJ, Rabinowitz D, Cavalli-Sforza LL, McKusick VA. Peripheral subresponsiveness to human growth hormone in the African pygmies. *N Engl J Med* 1969;281:1383–1388.
194. Merimee TJ, Baumann G, Daughaday W. Growth hormone binding protein II. Studies in pygmies and normal statured subjects. *J Clin Endocrinol Metab* 1990;71:1183–1188.
195. Geffner ME, Bailey RC, Bersch N, Vera JC, Golde DW. Insulin-like growth factor I unresponsiveness in a Efe pygmy. *Biochem Biophys Res Comm* 1993;193:1216–1220.
196. Salmon WD Jr, Daughaday W. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. *J Lab Clin Med* 1957;49:825–836.
197. Froesch ER, Burgi H, Ramseier EB, Bally P, Labhart A. Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. *J Clin Invest* 1963;42:1816–1834.
198. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, Van den Brande JL, Van Wyk JJ. Somatomedin: a proposed designation for the sulfation factor. *Nature* 1972;235:107.
199. Rinderknecht E, Humbel RE. Polypeptides with non-suppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. *Proc Natl Acad Sci USA* 1976;73:2365–2369.
200. Laron Z. Somatomedin-1 (recombinant insulin-like growth factor-1). Clinical pharmacology and potential treatment of endocrine and metabolic disorders. *BioDrugs* 1999;11:55–70.
201. Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. *Nature* 1980;287:781–787.
202. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology, with proinsulin. *J Biol Chem* 1978;253:2769–2776.
203. Brissenden JE, Ullrich A, Francke U. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. *Nature* 1984;310:781–784.
204. Mullis PE, Patel MS, Brickell PM, Hindmarsh PC, Brook CD. Growth characteristics and response to growth hormone therapy in patients with hypochondroplasia: genetic linkage of the insulin-like growth factor I gene at chromosome 12q23 to the disease in a subgroup of these patients. *Clin Endocrinol* 1991;34:265–274.
205. Rotwein P. Structure, evolution, expression and regulation of insulin-like growth factors I and II. *Growth Factors* 1991;5:3–18.
206. Werner H. Molecular biology of the Type I IGF receptor. In: Rosenfeld RG, Roberts CT Jr, eds. *The IGF System: Molecular Biology, Physiology and Clinical Applications*. Humana Press, Totowa, NJ, 1999, pp. 63–88.
207. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor binding protein (IGFBP) superfamily. *Endocr Rev* 1999;20:761–787.
208. Collet C, Candy J. At the cutting edge: how many insulin-like growth factor binding proteins? *Mol Cell Endocrinol* 1998;139:1–6.
209. Lewitt MS, Saunders H, Phuyal JL, Baxter RC. Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats. *Endocrinology* 1994;134:2402–2409.
210. Laron Z, Suikkairi AM, Klinger B, Silbergeld A, Pertzelan A, Seppala M, Koivisto VA. Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature. *Acta Endocrinol* 1992;127:351–358.
211. Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor-binding protein 3 in the absence of growth hormone activity. *Acta Endocrinol* 1993;128:144–149.

212. Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB. IGF binding protein-3 in patients with Laron-type dwarfism: effect of exogenous rIGF-1. *Clin Endocrinol* 1992;36:301–304.
213. Abbott AM, Bueno R, Pedrini MT, Murray JM, Smith RJ. Insulin-like growth factor I receptor gene structure. *J Biol Chem* 1992;267:10,759–10,763.
214. Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. *Proc Natl Acad Sci USA* 1989;86:114–118.
215. Bondy CA, Werner H, Roberts CT Jr, LeRoith D. Cellular pattern of insulin-like growth factor I (IGF-1) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-2 gene expression. *Mol Endocrinol* 1990;4:1386–1398.
216. Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-1 (IGF-1) receptor in IGF-1 action. *Mol Endocrinol* 1994;8:40–50.
217. Shemer J, Adamo M, Wilson GI, Heffez D, Zick Y, LeRoith D. Insulin and insulin-like growth factor-1 stimulate a common endogenous phosphoprotein substrate (pp185) in intact neuroblastoma cells. *J Biol Chem* 1987;262:15,476–15,482.
218. Kuhne MR, Pawson T, Lienhard GE, Feng GS. The insulin receptor substrate-I associate with the SH2-containing phosphotyrosine phosphatase Syp. *J Biol Chem* 1993;268:11,479–11,481.
219. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, et al. The function of GRB2 in linking the insulin receptor to ras signaling pathways. *Science* 1993;260:1953–1955.
220. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. *Endocr Rev* 1995;16:143–163.
221. Merimee TJ, Laron Z, eds. *Growth Hormone, IGF-1 and Growth: New Views of Old Concepts*. Freund Publishing House Ltd., London, 1996.
222. D'Ercole AJ, Applewhite GT, Underwood LE. Evidence that somatomedin is synthesized by multiple tissues in the fetus. *Dev Biol* 1980;75:315–328.
223. Nilsson A, Isgaard J, Lindhahl A, Dahlstrom A, Skottner A, Isaksson OGP. Regulation by growth hormone of number of chondrocytes containing IGF-1 in rat growth plate. *Science* 1986;233:571–574.
224. Baserga R. The IGF-1 receptor in cancer research. *Exp Cell Res* 1999;253:1–6.
225. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. *Mol Cell Biol* 1990;10:464–473.
226. Rosenfeld RG, Roberts CT Jr (eds). *The IGF System: Molecular Biology, Physiology and Clinical Applications*. Humana Press, Totowa, NJ, 1999, pp. 787.
227. Zapf J, Froesch ER. Insulin-like growth factor I actions on somatic growth. In: Kostyo J, ed. *Handbook of Physiology*, vol. V. American Physiol. Society, Washington DC, 1999, pp. 663–699.
228. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-1) and type I IGF receptor (IGF1r). *Cell* 1993;75:59–72.
229. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. *N Engl J Med* 1996;335:1363–1367.
230. Bierich JR, Moeller H, Ranke MB, Rosenfeld RG. Pseudopituitary dwarfism due to resistance to somatomedin: a new syndrome. *Eur J Pediatr* 1984;142:186–188.
231. Momoi T, Yamanaka C, Kobayashi M, Haruta T, Sasaki H, Yorifuji T, et al. Short stature with normal growth hormone and elevated IGF-1. *Eur J Pediatr* 1992;152:321–325.
232. Siebler T, Lopaczynski W, Terry CL, Casella SJ, Munson P, De Leon DD, et al. Insulin-like growth factor I receptor expression and function in fibroblasts from two patients with deletion of the distal long arm of chromosome 15. *J Clin Endocrinol Metab* 1995;80:3447–3457.
233. Tamura T, Tohma T, Ohta T, Soejima H, Harada H, Abe K, Niikawa N. Ring chromosome 15 involving deletion of the insulin-like growth factor I receptor gene in a patient with features of Silver-Russell syndrome. *Clin Dysmorphol* 1997;2:106–113.
234. Yakar S, Liu S-L, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. *Develop Biol* 1999;96:7324–7329.
235. Liu JL, LeRoith D. Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. *Endocrinology* 1999;140:5178–5184.
236. Laron Z. Short stature due to genetic defects affecting growth hormone activity. *N Engl J Med* 1996;334:463–465.

237. Clayton PE, Freeth JS, Norman MR. Congenital growth hormone insensitivity syndromes and their relevance to idiopathic short stature. *Clin Endocrinol* 1999;50:275–283.
238. Frankel JJ, Laron Z. Psychological aspects of pituitary insufficiency in children and adolescents with special reference to growth hormone. *Isr J Med Sci* 1968;4:953–961.
239. Kranzler JH, Rosenbloom AL, Martinez V, Guevara-Aguirre J. Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency: a controlled study in a genetically homogenous population. *J Clin Endocrinol Metab* 1998;83:1953–1958.
240. Laron Z, Galatzer A. A comment on normal intelligence in growth hormone receptor deficiency. (Letter to the Editor). *J Clin Endocrinol Metab* 1999;83:4528.
241. Woods KA, Clark AJL, Amselem S, Savage MO. Relationship between phenotype and genotype in growth hormone insensitivity syndrome. *Acta Paediatr* 1999;88(Suppl 428):158–162.
242. Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, et al. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. *J Clin Endocrinol Metab* 1997;82:3705–3709.



<http://www.springer.com/978-0-89603-860-8>

Developmental Endocrinology
From Research to Clinical Practice
Eugster, E.A.; Pescovitz, O.H. (Eds.)
2002, X, 421 p., Hardcover
ISBN: 978-0-89603-860-8
A product of Humana Press